Fighting SARS-CoV-2 with antibodies

Sep 13, 2020

CORAT SAB member Prof. Dr. Dübel explains how antibodies protect our body against coronavirus infections.

Share this entry

Latest news

€ 38.7 Mio. German government funding for the clinical development of a Corona medication

Jul 13, 2022

CORAT Therapeutics GmbH receives € 38.7 Mio. funding for the clinical development of COR-101, a drug to treat hospitalized COVID-19 patients with moderate to severe symptomsClinical processing of COR-101 is financially securedPreparation for market entry in 2023...

CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE

Jul 7, 2021

For the fast and efficient delivery of its innovative drug COR-101 against COVID-19, CORAT Therapeutics GmbH announces the partnership with Dermapharm Holding SE, a manufacturer of branded pharmaceuticals. With its own development, production facilities as well as...

CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant

Jun 22, 2021

Our laboratory tests indicate that COR-101 recognizes the particularly aggressive new „delta” variant B.1.617.2, which is rapidly replacing the “alpha” variant B.1.1.7Dr. Andreas Herrmann, CEO, CORAT Therapeutics On May 10th, the WHO classified the B.1.617.2...